Login to Your Account



Pharma: Clinic Roundup


Wednesday, April 4, 2012
• Bayer HealthCare Pharmaceuticals Inc., of Wayne, N.J., a subsidiary of Bayer AG, said its Phase III GRID (GIST – Regorafenib in Progressive Disease) trial evaluating investigational compound regorafenib (BAY 73-4506) in patients with progressive metastatic and/or unresectable gastrointestinal stromal tumors (GIST) met its primary endpoint of statistically significant improvement in progression-free survival.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription